A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial

Autor:	David Planchard, Sophie Postel-Vinay, Fabrice Barlesi, Rosa Rosell, B. Massuti Sureda, M.A. Sala Gonzalez, Santiago Viteri, A. Abou-Lauvergne, A. Gazzah, Benjamin Besse, J-C. Soria, M.R. Garcia Campelo, Jacques Cadranel, J. Coves Sarto, J.-P. Pignon, Carlos Camps, Margarita Majem, A.L. Ortega Granados, Jaafar Bennouna
Rok vydání:	2017
Předmět:	Oncology medicine.medical_specialty business.industry Phases of clinical research Hematology Placebo medicine.disease Poly (ADP-Ribose) Polymerase Inhibitor Olaparib Double blind chemistry.chemical_compound chemistry Internal medicine PARP inhibitor medicine In patient Lung cancer business
Zdroj:	Annals of Oncology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61c03d951bed21f01d84a02a7864eb88 https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7385 Zobrazit plný text záznamu